Diminished expression of Nrp1 in GBM cells leads to deregulation of this signaling balance, leading to VEGF-A independent angiogenesis and tumor recurrence following bevacizumab treatment (Fig 6). The gene discussed is VEGFA; the disease is glioblastoma.